Appendicitis Perforated
7
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Bilirubin Levels to Diagnose Appendicitis and Predict Appendiceal Perforation
Enhanced Recovery After Surgery (ERAS) for Complicated Appendicitis
Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population
Clinical Trial for a Outpatient Clinical Management for Complicated Acute Appendicitis
Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)
Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous
Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis